2023 POSTER PRESENTATIONS
Present your poster at the PEGS Boston Summit and be automatically entered to win. A winner will be chosen based on the clarity of the short text description, the novelty of data, technology advances and implications of the work presented, visual clarity of the poster presentation, and clear and engaging oral explanation.
Poster Award Winner Will Be Announced Wednesday, May 17 at 6:45pm
Poster Viewing Will Be Monday-Thursday in the Exhibit Hall.
P001: Fast Track Antigen-Specific B- and T-Cell Discovery Using Barcode Enabled Antigen Mapping (BEAM), Presented by Bruce A., 10x Genomics
P002: Out of the Box Tools for Antibody Characterization, Presented by Vera M., 2bind GmbH
P003: TCR Mimetic Antibody Discovery, Characterization, and Optimization Enabled by the AlphaSeq Platform, Presented by Emily E., A-Alpha Bio, Inc.
P004: Cytokine Affinity Tuning Using the AlphaSeq Platform to Generate Targeted Immuno-Oncology Therapeutics, Presented by Jeffrey A., A-Aplha Bio, Inc.
P005: Machine Learning Guided Antibody Optimization of a SARS-CoV-2 Binding Antibody Enabled by AlphaSeq, Presented by Randolph L., A-Aplha Bio, Inc.
P006: Custom-Build Optimal T-Cell Engagers for Diverse Tumor Targets with Differentiated CD3-Binding Antibodies, Presented by Raffi T., AbCellera Biologics, Inc.
P007: Breaking Barriers to Access Intracellular Targets with T-Cell Engagers: Discovery of Diverse, Developable, and Ultra-Specific Antibodies Against a MAGE-A4 pMHC, Presented by Davide T., AbCellera Biologics, Inc.
P008: High Throughput, High Fidelity Data Generation to Enable AI Lead Optimization, Presented by Vincent B., Absci Corporation
P009: Antibody Design Using Generative AI, Presented by Amir S., Absci Corporation
P010: Deep Learning-Based Codon Optimization with Large-Scale Synonymous Variant Datasets Enables Generalized Tunable Protein Expression, Presented by David S., Absci Corporation
P011: Comparing Potential Bispecific Formats of Trastuzumab and a Humanized OKT3, Presented by Michael F., Absolute Antibody
P012: Dual Action Antibodies for Treatment of Progressive Multiple Sclerosis, Presented by Hiep T., Abzyme Therapeutics
P013: Sequential Activation of Multiple Gene Copies Facilitates Adaptation of CHO Cells to Increased Productivity, Presented by Victor JL., ACIB GmbH
P014: SLAM-seq Reveals Early Transcriptomic Response Mechanisms upon Glutamine Deprivation in Chinese Hamster Ovary Cells, Presented by Maja P., ACIB GmbH
P015: Accelerating the Development of Novel Antibody-Drug Conjugates Through Site-Specific Conjugation Methods, Presented by An O., ACROBiosystems
P016: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-Throughput Yeast-Based Platform, Presented by Garrett R., Adimab LLC
P017: Investigating Thermal Stability of Nucleic Acids and Proteins Using the Agilent Cary 3500 UV-Vis Spectrophotometer, Presented by Ryan B., Agilent Technologies
P018: Site-Specific Incorporation of Non-Canonical Amino Acids by Proprietary Microbial Protein Expression System, Presented by Yumi N., Ajinomoto Co., Inc.
P019: From Peptides and Small Proteins to mAb, Ajinomoto's Proprietary Microbial Platform for Pharmaceutical Protein Production, Presented by Kazuo Y., Ajinomoto Co., Inc.
P020: Development of a Novel Anti-IL-5Ra Antibody with Improved Efficacy and a First-in-Class Bispecific T Cell Engager for Eosinophilic Asthma Therapy, Presented by Jun-Ho K., Ajou University
P021: Improved Intratumoral Penetration of IL12 Immunocytokine Enhances the Antitumor Efficacy, Presented by Seul Gi L., Ajou University
P022: Affinity-Guided Photocrosslinking Methodology for Site-Specific Conjugation of Antibody and Payload, Presented by Jisoo P., Ajou University
P023: Bispecific Antibodies Expand Therapeutic Breadth Across Divergent Filoviruses, Presented by Ariel W., Albert Einstein College of Medicine
P024: ATP128 Vaccine in Combination with Ezabenlimab Promotes Antigen-Specific Immune Responses in Stage IV Colorectal Cancer in KISIMA-01 Phase 1b Trial, Presented by Roberta P., Amal Therapeutics SA
P025: Primary Human Immune Cell Assays for the Evaluation of New Immuno-Oncology Therapies, Presented by Robert B., Antibody Analytics Ltd.
P026: Quantification of the Antigen Density Activation Threshold for Targeted Immunotherapeutics, Presented by Timothy L., Antibody Analytics Ltd.
P027: Capturing the Functional Antibody Repertoire from Multiple B-Cell Subsets Following Antigen Stimulation, Presented by John K., Antibody Solutions
P028: Gastric Cancer Antibody Fragment Drug-Conjugates (FDCs): Applying a Successful Concept to Solid Tumours, Presented by Mahendra D., Antikor Biopharma Ltd.
P029: Assessment of Statistical Significance of Minor Changes in HOS Using Circular Dichroism – A New Approach, Presented by Janel D., Applied Photophysics
P030: Tracking Changes in the Cellular Immune Response During Development of Multiple Myeloma from Premalignant to Malignant Disease, Presented by Suchita J., Ariel University
P031: Development of a High-Throughput Epitope Fingerprinting Method for Complex Membrane Proteins, Presented by Amy H., AstraZeneca
P032: Leap-In Transposases® - A New Paradigm in Cell Line Development, Presented by Oren B., ATUM
P033: Rapid Generation of Potent Antibodies by Autonomous Hypermutation in Yeast, Presented by Alon W., Aureka Biotechnologies
P034: A High Throughput Bispecific Antibody Discovery Pipeline, Presented by Weian Z., Aureka Biotechnologies
P035: Sequencing to Synthesis: Innovative Antibody Discovery Workflow Leveraging Biological Intelligence to Prioritize Leads, Presented by Ilaria D., Azenta Life Sciences
P036: Increasing IL-11 Function Blocking Antibody Binding Strength and Potency Using a Bi-Paratopic Antibody Format, Presented by Philipp E., Bayer AG
P037: An Anti-HER2/Trop-2 Bispecific Antibody-Drug Conjugate with a New DNA Topoisomerase I Inhibitor Exerts Potent and Broad Antitumor Activity in Preclinical Tumor Models, Presented by Helen Z., BiOneCure Therapeutics, Inc.
P038: Rapid and High Throughput Crude IgG Quantification For Ab Discovery and Development Using the Valita®Titer Assay
, Presented by Brian M., Beckman Coulter Life Sciences – ValitaCell
P039: NKp46 Engaging Bicycle NK- TICA™ Drives Tumor Targeted Cytotoxicity, Presented by Sandra U., Bicycletx Ltd.
P040: Using Conjugation Technology to Increase the Efficacy and Specificity of a MYC-Inhibiting Oligonucleotide, Presented by Samantha B., Binghamton University, State University of New York
P041: Design, Evaluation, and Optimization of Immune Stimulating Antibody-Drug Conjugates for Cancer Treatment, Presented by Siteng F., Binghamton University, State University of New York
P042: Pharmacology of Legumain-Cleavable MMAE Containing ADC Linkers, Presented by Meghan G., Binghamton University, State University of New York
P043: Novel Dual-Loaded ADC Elicits Both Cytotoxic and Immune-Modulating Effects in In-Vitro Pancreatic Cancer Model, Presented by Victor O., Binghamton University, State University of New York
P044: An Ultra-High-Throughput Screen for the Evaluation of Peptide HLA-Binder Interaction, Presented by Stefan K., BioCopy GmbH
P045: High Throughput Kinetic Characterization of a WT1 Specific TCR Like Antibody Using Novel pHLA Microarrays, Presented by Johannes W., BioCopy GmbH
P046: PEAKS AB 3.0: Accurate De Novo Sequence Assembly and Glycan Profiling of Antibodies, Presented by Kyle H., Bioinformatics Solutions, Inc.
P047: Biointron: A Proven and Reliable Alpaca VHH Antibody Discovery Platform, Presented by Shi L., Biointron Biological, Inc.
P048: Development of High Throughput Single-B Cell Antibody Discovery Platform, Presented by Shi L., Biointron Biological, Inc.
P049: Pioneer: A Novel Biotherapeutic Antibody Discovery Platform, Presented by Christian F., Bio-Rad AbD Serotec GmbH
P050: TrailBlazer: A Rapid Modular Antibody Assembly Platform, Presented by Christian F., Bio-Rad AbD Serotec GmbH
P051: Rapid Generation of Bispecific Antibodies for High-Throughput Screening, Presented by Christian H., Bio-Rad AbD Serotec GmbH
P052: Discovery and Development of Anti-CD40 Agonistic Antibody for Cancer Immunotherapy, Presented by Mingjiu C., Biosion, Inc.
P053: Streamlined Process for Automated Plasmid Purification Reduces Labour Time and Increases Titres for AAV Production, Presented by Shadie N., Biotage
P054: Evolution of a Hyperactive TcBuster™ Transposase Enables Highly Efficient Non-Viral Generation of CAR-NK and CAR-T Cells for Combination Cell Therapies, Presented by Neil O., Bio-Techne
P055: Trends in Industrialization of Biotherapeutics: A Survey of Product Characteristics of 89 Antibody-Based Biotherapeutics, Presented by Kyle M., Boehringer Ingelheim
P056: In Silico Prediction and In Vitro Fab Analysis of the Structural Basis of Lecanemab Paratope Binding Site, Presented by Jean-Pierre B., Brigham and Women's Hospital
P057: Tracing the Fate of Therapeutics-Conjugates at Subcellular Level via Imaging Mass Spectrometry, Presented by Christelle G., Brigham and Women's Hospital
P058: Development of Functionalized Microbead-Based Immunoassay by qPCR for the Detection of Amyloid-Beta(1-42) Monomer in Plasma, Presented by Jennifer P., Brown University
P059: CALIXAR’S Toolbox for Native Membrane Targets, Presented by Vincent C., CALIXAR
P060: Large-Scale Characterization of Drug Candidates Against Transmembrane Receptors Using HT-SPR, Presented by Nico A., Carterra, Inc.
P061: LSAXT: Extending the Applications Space of HT-SPR, Presented by Nico A., Carterra, Inc.
P062: Use of High Throughput SPR to Characterize Antibodies to Common Cancer Biomarkers, Presented by Nico A., Carterra, Inc.
P063: Biophysical Characterization of MR1 (K43A)/ß2M Complex, Presented by Sangeetha S., Cayman Chemical Company
P064: Role of Cancer Associated Glycan in the Regulation of Tumor Microenvironments, Presented by John Y., Chang Gung Memorial Hospital at Linkou
P065: Constrained Peptide Modeling, Conformational Analysis and Property Predictions, Presented by Philippe A., Chemical Computing Group
P066: Developability Assessment and Property Prediction by pH-Dependent Conformational Sampling, Presented by Nels T., Chemical Computing Group
P067: Functional Evaluation of Unique Anti-PDL1 Antibodies Generated Through Single Plasma B Cell Cloning on the Beacon® Platform Versus a Standard Hybridoma Approach, Presented by Mizanur R., ChemPartner USA
P068: Structural Characterization of Hsp40 Protein, Tid1 Using NMR, Presented by Jinhwa J., Chungbuk National University
P069: Development of an Ultra-High Affinity, Trimeric ACE2 Biologic as a Universal COVID Antagonist, Presented by Juliet G., City of Hope
P070: CB307: A Novel T-Cell Costimulatory Humabody VH Therapeutic for PSMA-Positive Tumours, Presented by Colette J., Crescendo Biologics Ltd.
P071: Fast-Tracking Development to Pre-Clinical: High Throughput and High Yield Transient Production in CHO and HEK293 Systems, Presented by Hans L., Curia
P072: A Scalable Single-Use Two-Step Plasmid Purification Process, Presented by Simon A., Cytiva
P073: Detection of Antigen-Specific IgG Isotypes in Crude Plasma by SPR, Presented by Olof K., Cytiva
P074: Investigating Complex Molecular Interactions Using Novel SPR Analysis Approaches, Presented by Olof K., Cytiva
P075: Doubling Process Productivity and Speeding Up Process Development with Mechanistic Modeling for Chromatography, Presented by John S., Cytiva
P076: bioMT Cores: Advancing Research at Dartmouth, Presented by Andreia V., Dartmouth College
P077: Unexpected Antibody-Like Stability and Characteristics of the Targeted Dual Cytokine Fusion Therapeutic, DK210(EGFR), Presented by David B., Deka Biosciences
P078: Development of Anti-CD73 Antibody for Cancer Immunotherapy, Presented by Chen-Jei H., Development Center for Biotechnology
P079: Training the Future of the Bioeconomy: Creating Accessible Research Experiences in Protein Engineering Using the Immune Epitope Database, Presented by Miko M., Digital World Biology
P080: DimAb® Single B Cell Cloning Platform and Its Application on CAR T-Cell Therapy Construct Development, Presented by Donghui M., DIMA Biotechnology Ltd.
P081: Rapid and High Throughput Biosensor Kinetics Screening in Early Antibody Discovery, Presented by Christina P., Distributed Bio, A Charles River Company
P082: Enzymatic DNA Synthesis (EDS) Allows Rapid Access to Synthetic Oligos to Produce Expression Vectors for SARS-CoV-2 Spike Variants, Presented by Raymond D., DNA Script
P083: Rapid, High Yield Eukaryotic Gene Expression Platform to Rival CHO; Faster, Higher Yield, Lower Cost Way to Develop and Manufacture Biologics, Presented by Joseph H., Dyadic International, Inc.
P084: Fully Automated Miniaturized Ultra-High Throughput Screening of Cells and Biomolecules, Presented by Martin M., Efficient Robotics GmbH
P085: Comprehensive and Fit-For-Purpose Solutions to Enable Drug Development for Cytokine Targets, Presented by Venkatesh C., Eurofins DiscoverX
P086: Accelerate Drug Development of GLP-1 and -2 Receptor Analogs with Ready-to-Use Cell-Based Assays, Presented by Debatri C., Eurofins DiscoverX
P087: EVOLVE – A Next-Generation CD2 Costimulation T Cell Engager Platform for Solid Tumors, Presented by Guixian J., EvolveImmune Therapeutics, Inc.
P088: Biophysical Characterization Roadmap for Developability Assessment During Antibody Discovery, Presented by Teresa B., FairJourney Biologics
P089: High Throughput Approaches for Production and Characterization in Antibody Discovery, Presented by Joana M., FairJourney Biologics
P090: Assessment of Sample Quality with Every Measurement, Presented by Ann Marie B., Fida Biosystems ApS
P091: Flow Induced Dispersion Analysis (FIDA) to Measure gRNA-Nuclease Interactions for CRISPR-Cas Development, Presented by Ann Marie B., Fida Biosystems ApS
P092: Rapid Sizing and Characterisation of Bispecific Antibodies, Presented by Ann Marie B., Fida Biosystems ApS
P093: Quantify and Characterize Any Protein Interaction – Even in Complex Backgrounds, Even with Challenging Targets, Presented by Gary R., Fluidic Analytics
P094: Discovery of Helical Peptide Therapeutics with Stapled Phage Display Screening, Presented by Olena T., FogPharma
P095: Evaluating the Versatility of Gator® Next Generation BLI Platform for Biotherapeutic Development and Gene Therapy, Presented by Harsha A., Gator Bio, Inc.
P096: Rapid and Easy Tool for Analyzing Viral and Lipid-Based Vectors Using BLI, Presented by Weijing G., Gator Bio, Inc.
P097: A Streamlined Data Analysis Workflow for Enhanced New Peak Detection (NPD) in the Multi-Attribute Method (MAM), Presented by Catherine E., Genedata AG
P098: Developing RNA Therapeutics with the Genedata Biopharma Platform, Presented by Jana H., Genedata AG
P099: A Streamlined Workflow for Analytical Characterization of Antibodies, Presented by Isabel K., Genedata AG
P100: Automating Assay Data Analysis Along the Discovery Pipeline, Presented by Isabel K., Genedata AG
P101: Yeast Surface Display of Full-Length IgG and Generation of Anti-Basigin Antibody, Presented by Youwei J., Genekine Biotech Co., Ltd.
P102: Systematic Pharmacological Analysis of Agonistic and Antagonistic Anti-FGFR1 MAbs Reveal a Similar Mechanism of Action, Presented by Joyce C., Genentech, Inc.
P103: Engineering PROTABs for Degradation of Cell Surface Receptors, Presented by Sheil K., Genentech, Inc.
P104: Don’t “FRET” Over It: Making (and Making Sense of) a Dually Conjugated DC-FRET Assay Detection Reagent, Presented by Justin L., Genentech, Inc.
P105: Mutually-Dependent IgG Antibody Combinations Engineered to Act Selectively on Cells Co-Expressing Two Antigens, Presented by Wilhem L., Genmab BV
P106: Characterizing Type III Kinase Inhibitor Using Laser-Free Flash Oxidation (Fox®) Hydroxyl Radical Protein Footprinting, Presented by Emily C., GenNext Technologies, Inc.
P107: Genovac Combines Multiple Species and Single B Cell Platforms to Increase Antibody Pool Diversity, Presented by Pete L., Genovac
P108: Effector Function Evaluation of Therapeutic Antibodies with Defined and Homogeneous Fc N-Glycans, Presented by Andrea P., Genovis AB
P109: Antibody Drug Development Solutions, Presented by Roumen B., GenScript
P110: Aura+: High Throughput, Low Volume Product Stability and Purity Analysis for Gene and Cell Therapies, Presented by Andrew S., Halo Labs
P111: Simultaneous Targeting of Primary Tumor, Draining Lymph Node, and Distant Metastases Through High Endothelial Venule-Targeted Delivery, Presented by Sungwook J., Harvard Medical School
P112: Immuno-Focusing a Leading Transmission-Blocking Vaccine Candidate by Epitope Masking Using Antigen Scaffolding and Glycan Engineering, Presented by Danton I., Hospital for Sick Children
P113: In Vitro Selection and Validation of Synthetic Single-Domain Antibodies and Applications, Presented by Brent P., Hybrigenics Services
P114: Incorporating Immobilized Enzymes in Tips on Liquid Handlers for Automated High-Throughput Glycomics and Proteomics Workflows, Presented by Dallas A., IMCS - Integrated Micro-Chromatography Systems, Inc.
P115: Incorporating Tip-Based Nucleic Acid Purifications on Liquid Handlers for Faster, Hands-Free Automation, Presented by Andrew L., IMCS - Integrated Micro-Chromatography Systems, Inc.
P116: Two Separate Chromatography Processes Using Tip-Based Protein Purifications on Liquid Handlers for Faster, Hands-Free Automation, Presented by Bill M., IMCS - Integrated Micro-Chromatography Systems, Inc.
P117: ImmTAAIs: TCR Targeted PD-1 Agonist Bispecifics for the Treatment of Autoimmune Diseases, Presented by David O., Immunocore Ltd.
P118: Targeting KRAS[G12D] Cancer Neoantigen with Soluble High Affinity T Cell Receptor Bispecific, Presented by Andrew P., Immunocore Ltd.
P119: IOS-1002-A Novel Multitarget Therapeutic Modulating 3 Checkpoint Pathways to Activate Both Adaptive and Innate Immunity, Presented by Anil K., ImmunOs Therapeutics AG
P120: Early Unwanted Immunogenicity Risk Assessment of Biotherapeutics, Presented by Chloe A., ImmunXperts, a Q² Solutions Company
P121: Functional Evaluation and Immunogenicity Assessment of Drug Candidates Using In Vitro Assays, Presented by Sofie P., ImmunXperts, a Q² Solutions Company
P122: In Vivo, Rapid Epitope and Paratope Mapping with Single Amino Acid Resolution, Presented by Faraz C., Immuto Scientific
P123: In-Vivo Structural Analysis and Epitope Mapping of Membrane Proteins In-Solution with Amino-Acid Resolution and High-Throughput, Presented by Hetal M., Immuto Scientific
P124: NMT Inhibitors as Novel Payloads for Antibody Drug Conjugates that Deliver Differentiated Activity, Presented by Josephine W., Imperial College London
P125: Isolation of Highly Selective Antibodies Against Claudin 18.2 and GPRC5D for Oncology Therapeutics, Presented by Ross C., Integral Molecular
P126: Characterization of SARS-COV-2 Antibodies Using Epitope Mapping and Pseudovirus Neutralization Assays, Presented by Ben D., Integral Molecular
P127: Screening the Membrane Proteome to Determine Antibody Specificity and De-Risk CAR-T Cell Development, Presented by Rachel F., Integral Molecular
P128: Development of CTIM-76, a Highly Specific Claudin 6 Bispecific Antibody for Treatment of Ovarian Cancer, Presented by Brad S., Integral Molecular
P129: Discovery of CCR8 Antibodies Targeting Regulatory T Cells to Enable Tumor Sensitization, Presented by Sharon W., Integral Molecular
P130: A Universal In Silico V(D)J Recombination Strategy for Developing Humanized Monoclonal Antibodies, Presented by Yuan-Chin H., I-Shou University
P131: Secondary Structure Estimation for Formulated Monoclonal Antibodies Using JASCO Spectra Manager 2.5 BeStSel CFR, Presented by Satoko S., JASCO Corporation
P132: Engineering Novel IgG Fc Glycosylation Sites for Bioconjugation, Presented by Zachary B., Johns Hopkins University
P133: Engineering Pan-Reactive VEGF Antagonists for Neovascular Eye Diseases, Presented by Paul S., Johns Hopkins University
P134: Hepassocin Acts to Ameliorate Inflammations and Liver Damage in Arthritis Model Mice, Presented by Mu-Shen C., Kaohsiung Medical University
P135: Developing a Pro-Immune Factor Antibody with a Spatial Hindrance Structure to Prevent Neutralization from Anti-Idiotypic Antibody and Enhance Therapeutic Efficacy, Presented by Yu-Tung C., Kaohsiung Medical University
P136: Targeting mPEGylated Liposome by One-Step Formulation with Bispecific Antibody to Enhance Therapeutic Efficacy in Hematologic Malignancies, Presented by Huei-Jen C., Kaohsiung Medical University
P137: Combining Methods of Clinical Protease Profiles and Automated Structure-Based Computational Simulation (MSCS 2.0) Enhances the Cleavability and Blocking Ability of the Disease-Activated Lock-Antibody, Presented by Tian-Lu C., Kaohsiung Medical University
P138: Developing a Universal Antibody Lock to Decrease the Immunogenicity of Antibody Drugs and Prolong the Pharmacokinetic of Pro-Antibody, Presented by Tzu-Yi L., Kaohsiung Medical University
P139: A Membrane-Tethered Chromogenic Enzyme System for Efficiently Monitoring Gene Expression, Presented by Wen-Wei L., Kaohsiung Medical University
P140: Development of a Bi-Specific Antibody (EphA2×mPEG) for Specific Targeting and Increase Endocytosis of Glycosidic Switch Liposomes to EphA2-Expressing Tumors, Presented by En-Shuo L., Kaohsiung Medical University
P141: Endogenous Anti-PEG Antibodies Reduce the Efficacy of COVID-19 mRNA Vaccine (BNT162b2), Presented by Yen-Ling L., Kaohsiung Medical University
P142: Characterization and Qualification of Adeno-Associated Virus Fill States Using Analytical Ultracentrifugation, Presented by Nikki M., KBI Biopharma
P143: Accelerated Development of Amber Codon Suppression Cell Line and a Bicistronic Vector Cell Line via Automated Gene Assembly System BioXP3250, Presented by Sharath M., Kemp Proteins
P144: Automated Viral Titer Methods Overestimate the Infectious Titer and Requires a Correction Factor Based on the Traditional IHC Assay, Presented by Grace V., Kemp Proteins
P145: Generation and Next Generation Sequencing-Based Characterization of a Large Human Combinatorial Antibody Library, Presented by Hye Lim C., Kookmin University
P146: Novel Bispecific Human Antibody Platform Specifically Targeting a Fully Open Spike Conformation Potently Neutralizes Multiple SARS-CoV-2 Variants, Presented by Ji Woong K., Kookmin University
P147: Development of Therapeutic Nonobodies Through Structural and Computational Design, Presented by Chandana S., Korea Research Institute of Bioscience and Biotechnology
P148: Unlocking the Full Potential of IgG Antibodies: Fc Variants Engineered for Enhanced Target Cell Clearance, Silenced Effector Function, or Prolonged Serum Persistence, Presented by Sang Taek J., Korea University
P149: A High-Throughput Platform for Targets Screening by Membrane Protein Library, Presented by Stephanie W., Kyinno Biotechnology
P150: A Machine Learning-Driven Approach for the Multiparametric Lead Optimisation of Anti-Tumour T-Cell Engagers, Presented by Michael M., LabGenius
P151: ALiCE- Simple Reaction Radical Results. Facile Scaling of Eukaryotic Cell-Free Protein Synthesis from Microliter to Liter Volumes with Consistent Yields, Presented by Andreas K., LenioBio GmbH
P152: Rapid Screening and Scaled Manufacture of Immunogenic Virus-Like Particles in a Tobacco BY-2 Cell Free Protein Synthesis System, Presented by Andreas K., LenioBio GmbH
P153: Singularity Mice: A Novel Genetic Platform for Developing Single Domain Antibodies and Multi-Specific Antibodies, Presented by Weisheng C., Leveragen
P154: Bottlenecks in Cell, Gene and mRNA Therapy: SUMO-Fusion to the Rescue, Presented by Abdul H., LifeSensors, Inc.
P155: Predictive Modeling of Concentration-Dependent Viscosity Behavior of Monoclonal Antibody Solutions Using Artificial Neural Networks, Presented by Christoph G., Lonza AG
P156: Satisfying Regulatory Requirements Using Orthogonal Methods for Glycosylation Analysis: An Example with a Monoclonal Antibody, Presented by Paulina U., Ludger Ltd.
P157: A Novel Universal Antibody-Based Adaptor Platform for Cancer Immunotherapy, Presented by Marlena S., Ludwig Maximilian University
P158: Cell Avidity Drives the Functional Responses of Immunotherapies with Superior Correlates to In Vivo Performance, Presented by Will S., LUMICKS
P159: Production of Fusion Bispecific Antibodies Using an Alternating Tangential Flow (ATF) Perfusion Culture System, Presented by Shaoyang Y., MabPlex
P160: STR: The First and Only Truly Silent Fc Technology, Presented by Ian W., mAbsolve
P161: Illuminating the Cellular Uptake of HaloTag and Its Localization via a pH-Sensitive Fluorophore, Presented by JoLynn G., Massachusetts Institute of Technology
P162: Site-Specific Antibody Conjugation Through Bisected N-Glycans with the Preserved Glycoengineering Capability, Presented by Yen-Pang H., Merck & Co., Inc.
P163: Automated Protein Normalization: Enhanced Efficiency and Reproducibility Using Lynx VVP Technology, Presented by Catherine R., Merck & Co., Inc.
P164: Fully Automated, HT Protein Production from Transient ExpiCHO Expressions: Method Development and Optimization, Presented by Kendal W., Merck & Co., Inc.
P165: Discovery and Engineering of Potent Notch Modulators, Presented by Elliot M., Moffitt Cancer Center
P166: Protein Engineering Reveals Structural Insights into LAG3 Immunosuppressive Function, Presented by Qianqian M., Moffitt Cancer Center
P167: Bispecific Nanobodies for Detection of Axillary Lymph Node Metastases in Breast Cancer, Presented by Srishti S., Moffitt Cancer Center
P168: Mesothelin-Targeting Bispecific T Cell Engagers that Retain Anticancer Activity upon Exposure to Shed Mesothelin, Presented by Anirban C., National Institutes of Health, National Cancer Institute
P169: Dromedary Camel Nanobodies Neutralize SARS-CoV-2 Variants, Presented by Jessica H., National Institutes of Health, National Cancer Institute
P170: Camel Nanobody-Based B7-H3 CAR-T Cells with High Efficacy Against Large Solid Tumors, Presented by Dan L., National Institutes of Health, National Cancer Institute
P171: Engineering T Cells Targeting GPC2 for Treating Neuroblastoma, Presented by Alex Q., National Institutes of Health, National Cancer Institute
P172: Identification and Structural Analyses of Highly Protective Anti-Malarial Antibodies, Presented by Prabhanshu T., National Institutes of Health, National Institute of Allergy and Infectious Diseases
P173: Structure-Guided Engineering of a High-Affinity Anti-Methoxy Poly(ethylene Glycol) Antibody for Sensitive Immunosensing of mPEGylated Therapeutics, Presented by Yu-Cheng S., National Yang Ming Chiao Tung University
P174: An E. coli Cell Lysate Based System for In Vitro Protein Synthesis, Presented by Paula M., New England Biolabs, Inc.
P175: A Broad-Specificity O-Glycoprotease Enables Improved Analysis of Glycoproteins and Glycopeptides Containing Intact Complex O-Glycans, Presented by Saulius V., New England Biolabs, Inc.
P176: Discovery of Potent and Functional Fully Human Antibodies Against CD36 for Cancer Immunotherapy, Presented by Musheng B., Nona Biosciences
P177: HBM9014 Is a Fully Human Anti-LIFR Antibody with Excellent Preclinical Efficacy and Safety Profile, Presented by Joe Z., Nona Biosciences
P178: The Silicon Germinal Center® (SGC): Screening Recombinant Antibodies in Mammalian cells with Reversible Membrane Display, Presented by Scott D., OCMS Bio
P179: Discovery of High Affinity Antibodies Against a GPCR Target by mRNA Immunization of OmniChicken®, Presented by Vivian H., OmniAb, Inc.
P180: PSCA Expressions in Cancers: A Potential Prognostic Marker and Target for Immunotherapy, Presented by Yichen G., OriGene Technologies, Inc.
P181: FcyRIIa-Specific DARPins as Novel Tools in Blood Cell Analysis and Platelet Clotting, Presented by Samuel T., Paul Ehrlich Institut
P182: Application of LabChip Empty/Full Microfluidic Assays for AAV2 and AAV9 Analysis, Presented by Dipti M., PerkinElmer
P183: Measurement of AAV Protein Composition and Empty/Full Analysis Using Microfluidics, Presented by James W., PerkinElmer
P184: High-Throughput Cell-Free In Vitro Protein Expression, Purification, and Functional Evaluation on Beacon Optofluidic System, Presented by Or G., PhenomeX
P185: Multi-Omic Analysis for Directly Linking T Cell Phenotype to Gene Expression, Presented by Or G., PhenomeX
P186: Lenti.RiGHT – Epigenetic Targeting Delivers Cutting-Edge Lentivirus Producer Cell Lines, Presented by Volker S., ProBioGen AG
P187: Novel Bioluminescent Bioassays for the Discovery and Development of Molecular and Cellular T Cell Redirecting Therapy, Presented by Mei C., Promega Corporation
P188: Development of Bioluminescent No-Wash Fc Gamma Receptor Binding Immunoassay to Guide the Development of Antibody Therapeutics, Presented by Kai H., Promega Corporation
P189: Cell-Based Luminescent Reporter Bioassays for Immunotherapies Targeting Macrophage Effector Functions, Presented by Lennart B., Promega Corporation
P190: Novel icIEF-Based Fractionation of Therapeutic Antibody Charge Variant for LC-MS Characterization, Presented by Jessica D., ProteinSimple, a Bio-Techne Brand
P191: Rapid Purity and Charge Heterogeneity Analysis of Anti-CD4 mAb Culture Variants by Maurice™, Presented by Yasef K., ProteinSimple, a Bio-Techne brand
P192: Development of Gemtuzumab-Targeted Dual-Drug Loaded Nanoparticles for the Treatment of Paediatric Acute Myeloid Leukaemia, Presented by Ana C., Queen's University Belfast
P193: Engineering Anti-Malarial Antibody with High Affinity by Reiteration of Site Saturation Mutagenesis and High-Throughput Screening, Presented by Jihwan C., Ragon Institute of Mass General, MIT, and Harvard
P194: Enhanced Antibody Recognition Against HIV Resistant Strains by Directed Evolution, Presented by Matheus O., Ragon Institute of Mass General, MIT, and Harvard
P195: Immortalization and Functional Analyses of Human Natively Paired Antibody Repertoires from HIV-1 Chronically Infected Patients, Presented by Xiaoli P., Ragon Institute of Mass General, MIT, and Harvard
P196: Exploring the Potential of Antibody Discovery Through Proteomics and De Novo Sequencing of Polyclonal Antibodies: An Alpaca Case Study, Presented by Anthony S., Rapid Novor
P197: Structure, Stability, Similarity, and Stress Characterization of Trastuzumab and Two Biosimilar Drugs Using Microfluidic Modulation Spectroscopy (MMS), Presented by David S., RedShift Bio
P198: Measuring Protein-Protein Interactions with Mass Photometry, Presented by Kate S., Refeyn, Inc.
P199: Multidomain Peptide Hydrogels as Scaffolds for T-Cell Applications, Presented by Viridiana LA., Rice University
P200: Engineering of DutaFabs, Presented by Davide B., Roche Diagnostics GmbH
P201: Modeling NGS Data from Display Campaigns with Gaussian Processes, Presented by Wing Ki W., Roche Diagnostics GmbH
P202: Development of Anti-Host Cell Protein Antibodies and Reagent Qualification using Orthogonal Analytical Methods, Presented by Dan K., Rockland Immunochemicals, Inc.
P203: Discovery of Novel Therapeutics Against GPCRs, Ion Channels and Transporters with the Salipro Platform, Presented by Sara B., Salipro Biotech AB
P204: DEVELOPICK™: Samsung Biologics Developability Assessment Platform - A Rapid and Accurate Evaluation Tool for Molecular Stability, Presented by Seahee K., Samsung Biologics
P205: Increasing Productivity in Biologics Development by Using Octet® Bio-Layer Interferometry Platforms, Presented by Nilshad S., Sartorius
P206: Simplifying Data Compliance for Multi-Channel Capillary Electrophoresis, Presented by Philip H., SCIEX
P207: Single-Cell Interactive Cytometry Using Made-to-Order Droplet Ensembles, Presented by Russell C., Scribe Biosciences
P208: Prophylactic Epstein Barr Virus Vaccine Design with Engineered Prefusion Stabilized gB Variants, Presented by Bianka H., Seattle Children's Research Institute
P209: ROR1 VHH Therapeutic Design, Presented by Jason P., Seattle Children's Research Institute
P210: Augmenting Ex Vivo T Cell Activation and Expansion with Soluble Circular Tandem Repeat Protein Scaffolded Agonists, Presented by Raymond R., Seattle Children's Research Institute
P211: Identifying Ig Selective Proteases for Treatment of Autoimmune Disease Using the IMPACT Platforms, Presented by June S., Seismic Therapeutic
P212: Development and Deimmunization of Protein Therapeutics by Machine Learning, Presented by Nathan R., Seismic Therapeutic
P213: Discovery and Characterization of FcgRIIb Specific mAbs, Presented by Elliott W., Seismic Therapeutic
P214: H-map: Amino Acid Generator for Designing and Scoring Protein Binders Without Backbone Structure Information, Presented by Hyeonuk W., Seoul National University
P215: BA1302, a Novel, Investigational CD228-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors, Presented by Shuo W., Shandong Boan Biotechnology Co. Ltd.
P216: A Novel ROR1/CD3 Bispecific TCE with Excellent ROR1 Specific Killing Effect, Presented by Jinghua G., Shanghai Taijin Biotechnology Co., Ltd.
P217: Molecular Guidance Systems (MGS) as a Versatile Vehicle for Cell-Specific Targeted Delivery of Nucleic Acid Therapeutics, Presented by Michael M., SRI International
P218: Going Beyond the Blood-Brain Barrier: Delivery of Diverse Cargo to Targeted Cells Within the Central Nervous System, Presented by Amanda P., SRI International
P219: Expanding Cancer Immunotherapy by Exploiting Recall Immunity – A New Co-Therapy Option for Checkpoint Inhibitors, Presented by Indu V., SRI International
P220: Targeting Treg Cells by TNFR2 Antibody Induces Tumor Regression In Vivo, Presented by Wenwu Z., Staidson Biopharma, Inc.
P221: EcCustom: A Platform for Customizing E. coli for Recombinant Protein Production, Presented by Alexandros K., Stockholm University
P222: CRBN Is Downregulated in Lung Cancer and Negatively Regulates TLR2,4 and 7 Stimulation in Lung Cancer Cells, Presented by Mi-Jeong K., Sungkyunkwan University
P223: Stratifin (SFN) Regulates Lung Cancer Progression via Nucleating the Vps34-BECN1-TRAF6 Complex for Autophagy Induction, Presented by Jiyoung K., Sungkyunkwan University
P224: Discovery of STRO-003, a Novel ROR1 Targeting ADC Using Cell Free Protein Synthesis and Site-Specific Conjugation Technologies, Presented by Garrett G., Sutro Biopharma, Inc.
P225: Half-Life Extended Engineered IL18 Variants that Escape the Negative Regulation of IL18BP, Presented by Eunice K., Sutro Biopharma, Inc.
P226: Development of an iLite® Reporter Cell Platform for the Quantification of Anti-AAV Neutralizing Antibodies, Presented by Jordi RM., Svar Life Science
P227: Functional Bioassays Measuring the Potency of Complement Therapeutics, Presented by Therese S., Svar Life Science
P228: Quantification of Bispecific Antibody-Mediated T-Cell Activation with Engineered CD3 Effector and Tailored Target Cells, Presented by Therese S., Svar Life Science
P229: First-in-Class Non-Genetic Generation of DAR1 Antibody-Conjugates for Application with Ultra-Potent Payloads and Immune Cell Engagers, Presented by Sander V., Synaffix
P230: Preclinical Assessment of GlycoConnect™ ADCs with Potency-Modulated Analogues of PNU-159,682, Presented by Floris V., Synaffix
P231: Optimized Receptor Design to Improve CAR-T Cell Efficacy, Presented by Maeta S., Sysmex Corporation
P232: Rapid Production of EGFR-Specific Armed T Cells Using a Non-Genetic Engineering Platform, Presented by Michael C., Taipei Medical University
P233: Development of Antagonistic BACE-2 Antibodies to Improve Type 2 Diabetes by Inducing Pancreatic Beta-Cells Proliferation, Presented by Kuo-Hsiang C., Taipei Medical University
P234: Dual Blockade of HSP90/HDAC6 Effectively Destroys the Immunosuppressive Tumor Microenvironment and Prevents Tumor Recurrence, Presented by Tung Yun W., Taipei Medical University
P235: Identification of Bioanalytical Antibodies Using Digital SPR, Presented by Brian W., Nicoya
P236: Development of a NanoString-Based High-Throughput miRNA Detection Workflow for Mouse Whole Blood and Serum Samples, Presented by Josephine F., Takeda Pharmaceutical Co. Ltd.
P237: Identification of Binning Diversity and Binding Properties of SARS-CoV-2 Antibodies Using Carterra LSA, Presented by Hazal K., Takeda Pharmaceutical Co. Ltd.
P238: High Throughput CAR Cell Production and Characterization with Repeat Antigen Stimulation Assay, Presented by Sophie M., Takeda Pharmaceutical Co. Ltd.
P239: High Throughput Multiplex Protein and Cell Based Binding Assay Development for Phage Display Antibody Discovery, Presented by Nicholas T., Takeda Pharmaceutical Co. Ltd.
P240: Discover Potent and Selective Antibodies Using a Yeast Display Platform, Presented by Weihong Y., Takeda Pharmaceutical Co. Ltd.
P241: Multi-Specific c:Met x EGFR x VEGF Antibody for Difficult to Treat Cancers, Presented by Mark T., Tavotek
P242: TavoSelect Process Generates Multiple Diverse Single Domain Epitope Bins, Presented by Mark T., Tavotek
P243: In Vivo Detoxification of Amatoxin-Based ADCs (ATACs®) by “Click” Chemistry, Presented by Alessandra T., Technical University of Munich
P244: Rational Crystal Contact Engineering as a Tool for Enhancing Preparative Protein Crystallization, Presented by Brigitte W., Technical University of Munich
P245: Sequence In, mRNA Out. A New Paradigm to Accelerate Discovery of mRNA Vaccines and Therapeutics, Presented by Ankita D., Telesis
P246: Flow Cytometry: Applications and Considerations in Analytical Methods Development and Qualification, Presented by Huan C., Teva Pharmaceuticals
P247: Site-Specific Conjugation of Novel Fluorophores, Molecular Imaging Reagents, and ADC Toxins to Streamline Immunotherapy Discovery and Development, Presented by Brian A., Thermo Fisher Scientific
P248: Accelerating Discovery and Rational Design of Biologics with Cryo-EM, Presented by Pascal L., Thermo Fisher Scientific
P249: Setting Up an Effective Protein Expression Workflow, Presented by Matt M., Thermo Fisher Scientific
P250: High-Throughput Protein Production Enables Rapid Identification of Variants Exhibiting Desired Characteristics, Presented by Zachary S., Tierra Biosciences
P251: Modeling Anti-Cancer Therapies in Advanced Human Immune System Mouse Models, Presented by Kiave H., TransCure bioServices
P252: Discovery of Functional Anti-DKK1 Antibodies with an Integrated Platform, Presented by Zhen H., Twist Bioscience
P253: Leveraging Twist’s Library of Libraries for The Identification and Functional Antibody Validation for LAG-3 Immunotherapy, Presented by Wes S., Twist Bioscience
P254: Pyridazinediones, a Modular Platform for the Development of Next-Generation Protein Conjugates: From Chemical Construction of Bispecifics and Tuneable Payload Conjugates to Reversible Cysteine Modification, Presented by Lea R., University College London
P255: CAR T Cells Are Effective at Treating Aggressive Fungal Infections, Presented by Michelle S., University Hospital Wuerzburg
P256: Long-Lasting Expression of Transgenes in Mouse Primary Fibroblast-Like Synoviocytes with Self-Amplifying RNA, Presented by Tony L., University of Cambridge
P257: Affinity Maturation of Computationally Designed Fragment for Next-Generation Nanobody Discovery, Presented by Xing X., University of Cambridge
P258: Single Molecule FRET Reveals Protein Dual Stabilization Mechanism in an Immobilization Support, Presented by Hector SM., University of Colorado, Boulder
P259: Rabbit Derived VL Single-Domain Antibodies Scaffolds and In Vivo Phage Display Selections as a Promising Platform to Develop Highly Specific and Potent Antibody-Drug Conjugated Compounds, Presented by Frederico A., University of Lisbon
P260: ITGA4 Knockout Prevents Blood-Brain-Barrier Migration of CAR T Cells, Presented by Kenneth D., University of Maryland, Baltimore
P261: A Novel Interpretable Machine Learning Method Enables Prediction of Continuous Properties and Accelerates Protein Engineering Tasks from Directed Evolution Experiments, Presented by Marshall C., University of Michigan
P262: A Mechanistic Study of Enhertu and Kadcyla Reveals the Importance of Matching Payload Delivery with its Potency, Presented by Shujun D., University of Michigan
P263: High Avidity, Low Affinity Antibody Optimizes Antibody Drug Conjugate Tissue Penetration at Multiple Expression Levels, Presented by Anna K., University of Michigan
P264: Development of HER2+ Syngeneic Model for Understanding ADC in Clinical Success, Presented by Hyeyoung K., University of Michigan
P265: Synthetic Mini-Protein Scaffolds to Engineer Developable Ligands for Immune Modulation and Insulin Receptor Antagonism, Presented by Paul B., University of Minnesota
P266: Characterizing Antibody Internalization for Rational Selection of ADC Linker Design, Presented by Zekun S., University of Minnesota
P267: Controlled Fab-Arm Exchange on mAb² Pairs for the Production of Multipecific Antibodies, Presented by Veronica N., University of Natural Resources and Life Sciences
P268: Bispecific Antibodies for Allergy Treatment, Presented by Aleksandra R., University of Natural Resources and Life Sciences
P269: Decoding Amyloidosis in Human Antibody Light Chains, Presented by Puneet R., University of Oslo
P270: Elastin-Like Polypeptides (ELPs) for the Delivery of αB Crystallin Peptide to the Retinal Pigment Epithelial Cells, Presented by Sara A., University of Southern California
P271: Multicomponent Reaction for the Site-Selective Conjugation of Monoclonal Antibodies, Presented by Ilias K., University of Strasbourg
P272: A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Potent Antibody-Drug Conjugates, Presented by Lorenzo T., University of Strasbourg
P273: Antibodies Neutralizing the Adenylate Cyclase Toxin Synergize with Anti-Pertactin Antibodies to Protect Mice Against B. pertussis, Presented by Dzifa A., University of Texas at Austin
P274: Generation of Highly Selective Monoclonal Antibodies Inhibiting Matrix Metalloproteinases by Periplasmic Genetic Selection, Presented by Ki Baek L., University of Texas at Houston
P275: High-Fidelity Large-Diversity Monoclonal Mammalian Cell Libraries by Cell Cycle Arrested RMCE, Presented by Zening W., University of Texas at Houston
P276: Functional Delineation of a Protein–Membrane Interaction Hotspot Site on the HIV-1 Neutralizing Antibody 10E8, Presented by Sara IG., University of the Basque Country
P277: Development of Novel Biotherapeutic Agents for Tumor-Specific Delivery of Cytotoxic Agents, Presented by Izaskun M., University of the Basque Country
P278: Development of Nanobodies Based Chimeras as Synthetic Calibrators for Immunodiagnosis, Presented by Gabriel L., University of Uruguay
P279: A Variable Lymphocyte Receptor Capable of Delivering Therapeutics to Glioblastoma, Presented by Elizabeth A., University of Wisconsin, Madison
P280: Native Complex Membrane Antigen Expression on Poxvirus for Antibody Discovery, Presented by Maria S., Vaccinex
P281: Increased Productivity with Rapid CIP Using GORE Protein Capture Devices with Protein A and Demonstrated Scalability, Presented by Lauren P., W. L. Gore & Associates, Inc.
P282: Novel Tyrosine Click Chemistry Platform to Access Bispecific T-Cell Engagers, Presented by Irene S., Wageningen University and Research
P283: Improving Analysis of Quality Indicating Attributes for Better Lifecycle Management, Presented by Robert B., Waters Corporation
P284: Overcoming the Challenges in Asymmetric Bispecific Antibody Production by Using Quick’n Clean Platform, Presented by Mark C., WuXi Biologics
P285: Discovery of a Cynomolgus Monkey-Cross-Reactive Anti-Human CD3 mAb for T Cell Engagers, Presented by Siwei N., WuXi Biologics
P286: Overcoming Technical Challenges with BsAbs and MsAbs Using Novel Technology Platforms, Presented by Siwei N., WuXi Biologics
P287: Integrated Analytical Platform to Support Biologic Drug Discovery and Beyond, Presented by Yongsheng X., WuXi Biologics
P288: Tumor-Specific CD28 Costimulatory XmAb Bispecific Antibodies Enhance T Cell Activation in Solid Tumors, Presented by Matthew F., Xencor, Inc.
P289: Fully AI-Driven Humanoid VHH Phage Library, Presented by Yunfei L., XtalPi, Inc.
P290: TriTCE Co-Stim, Next Generation Costimulatory Trispecific T Cell Engagers for the Treatment of Solid Tumors, Presented by Purva B., Zymeworks, Inc.
P291: Optimization of Purine-Based TLR7 Agonists as Payloads for Immune-Stimulating Antibody Conjugates (ISACs), Presented by Graham G., Zymeworks, Inc.
P292: Alco5 – Technology-Enabled Payload Solutions to Broaden the Scope of Conjugatable Drugs, Presented by Jonas HS., Tubulis GmbH
P293: Development of a Drug Discovery Platform with Phage Displayed Cystine Knot Peptide Scaffolds and Discovery of Potent and Stable Peptide Antagonists Against VEGF, Presented by Lijuan Z., Genentech, Inc.
P294: Pelican Expression Technology® - A Versatile and Robust Protein Expression Platform for the Development of Next Generation Protein Therapeutics, Presented by Adam C., Ligand Pharmaceuticals
P295: SARS-CoV-2 Neutralizing Antibodies Discovered Across Three Individuals Following Vaccination and Infection Show Diverse Epitopes Across Virus Spike Protein, Presented by Thiago L., Abterra Biosciences
P296: Long-Term Virologic Suppression Following AAV Delivery of Anti-HIV Monoclonal Antibodies, Presented by Jose MN., University of Miami
P297: A Faster and Sensitive CHO HCP Impurity Quantification Workflow - AlphaLISA® & HTRF® CHO Host Cell Protein Kits, Presented by Jordan A., PerkinElmer
P298: AlphaLISA Adeno Associated Virus (AAV) Kits – A Faster and More Sensitive AAV Capsid Detection Method, Presented by Daniel C., PerkinElmer
P299: Cell Identity, Count, and Viability for Critical Quality Attributes Using the Cellaca® PLX Image Cytometer, Presented by Pragnesh P., PerkinElmer
P300: Rapid No Wash Assays for Characterizing a Mouse TIGIT/PD-L1 Bispecific Antibody, Presented by Jerry P., PerkinElmer
P301: Development of an Immunomodulatory AAV Viral Vector to Minimizing Adaptive Immune Responses to AAV-Delivered Broadly Neutralizing Antibodies, Presented by James T., University of Miami